Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473248 | 0.86 | TSHR (0.37) | TSHR | |
| SCHEMBL2348007 | 0.80 | — | — | |
| SCHEMBL31679616 | 0.77 | — | — | |
| SCHEMBL17017282 | 0.77 | — | — | |
| SCHEMBL5164728 | 0.74 | — | — | |
| SCHEMBL19210228 | 0.73 | — | — | |
| SCHEMBL17017289 | 0.67 | FAAH (0.39) | TSHR | |
| SCHEMBL18092328 | 0.67 | FAAH (0.39) | TSHR | |
| SCHEMBL5164541 | 0.67 | TSHR (0.30) | TSHR | |
| SCHEMBL15290275 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0670838-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO 4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1995-09-13 | — | — | EP | claimed |
| WO-1994012500-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO[4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1994-06-09 | — | — | WO | claimed |
| US-5262426-A | Treatment of cardiovascular disorders, antiinflammatory agents | G. D. SEARLE & CO. (US) | 1993-11-16 | — | — | US | claimed |
| US-8124704-B2 | Conjugated diene polymer, conjugated diene polymer composition, and process for producing conjugated diene polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20090247692-A1 | CONJUGATED DIENE POLYMER, CONJUGATED DIENE POLYMER COMPOSITION, AND PROCESS FOR PRODUCING CONJUGATED DIENE POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20060100465-A1 | METHOD FOR HALOGENATING OR RADIOHALOGENATING A CHEMICAL COMPOUND | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-05-11 | — | — | US | disclosed |
| US-7041859-B1 | Method for halogenating or radiohalogenating a chemical compound | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2006-05-09 | — | — | US | disclosed |
| EP-0670838-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO 4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994012500-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO[4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5262426-A | Treatment of cardiovascular disorders, antiinflammatory agents | G. D. SEARLE & CO. (US) | 1993-11-16 | — | — | US | disclosed |
| US-4395418-A | 6-HYDROXYETHYL SUBSTITUTED ANTIBIOTICS | SANKYO COMPANY LIMITED (JP) | 1983-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100465-A1 | METHOD FOR HALOGENATING OR RADIOHALOGENATING A CHEMICAL COMPOUND | AOX1, TPO, LPO | TSHR 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.